NCT02100007终止1 期
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 46
- 试验地点
- 10
- 主要终点
- Number of Adverse Events
研究概览
简要总结
The purpose of this study is to determine the safety and tolerability of ME-344 when given in combination with Hycamtin® in patients with solid tumors
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologic or cytologic confirmed locally advanced or metastatic small cell lung cancer, ovarian cancer, or cervical cancer (Part 1); small cell lung cancer and ovarian cancer (Part 2)
- •Patients with ovarian and small cell lung cancer must have failed initial therapy
- •Patients with carcinoma of the cervix must have advanced disease not amenable to curative surgery and/or radiation therapy
- •Patients may not have received more than 4 prior regimens of therapy
- •Patients may not previously have received irinotecan, topotecan or other topoisomerase I inhibitor
- •ECOG Performance status 0-1 (Appendix B)
- •A minimum life expectancy of 12 weeks
- •Adequate bone marrow, hepatic and renal function as evidenced by:
- •Absolute neutrophil count (ANC) > 1.5 x 109/L
- •Platelet count > 100 x 109/L
- •Hemoglobin > 9.0 g/dL
- •Serum bilirubin < 1.5 x ULN
- •AST/ALT (SGOT/SGPT) < 2.5 x ULN for the reference laboratory or < 5 x --ULN in the presence of liver metastases
- •Serum creatinine < 1.5 x ULN or creatinine clearance ≥ 60 mL/min as measured by institutional standards
- •At least 21 days must have elapsed prior to Day 1 Cycle 1, since any radiotherapy, immunotherapy or following major surgery; any surgical incision should be completely healed. At least 14 days must have elapsed prior to Day 1 Cycle 1 since "limited palliative radiotherapy", defined as a course of therapy encompassing <25% total bone marrow volume and not exceeding 30 GY.
排除标准
- •Patients with tumor involvement of the Central Nervous System (CNS). SCLC patients with previously treated CNS lesions must have stable CNS disease for at least 4 weeks
- •Patients with uncontrolled infection or systemic disease
- •Patients with clinically significant cardiac disease not well controlled with medication (e.g., congestive heart failure, symptomatic coronary artery disease e.g. angina, and cardiac arrhythmias) or myocardial infarction within the last 12 months
- •Patients who have toxicity from last prior therapy that has not recovered to at least Grade 1, with the exception of Grade 2 alopecia
- •Patients who have had any chemotherapy regimens, biologic, or targeted therapies within the 2 weeks prior to Cycle 1 Day 1
- •Patients with any neuropathy > Grade 1
- •Patients with known hypersensitivity to any components of ME-344 or topotecan study drug product
- •Patients with known human immunodeficiency virus (HIV) or Hepatitis B or C (active, previously treated or both)
- •Patients with a history of solid organ transplantation
- •Patients with presence of concurrent or active malignant disease (other than disease under study) within the last 12 months with the exception of adequately treated in-situ carcinomas, basal or squamous cell carcinoma, or non-melanomatous skin cancer.
- •Patients with any psychiatric disorder or social or geographic situation that would preclude study participation
研究组 & 干预措施
ME-344
Experimental
ME-344 IV, 10 mg/kg on Days 1, 8, 15 and 22 of each 28 day cycle Topotecan IV, 4 mg/m2 on Days 1, 8 and 15 of each 28 day cycle
干预措施: ME-344 (Drug)
ME-344
Experimental
ME-344 IV, 10 mg/kg on Days 1, 8, 15 and 22 of each 28 day cycle Topotecan IV, 4 mg/m2 on Days 1, 8 and 15 of each 28 day cycle
干预措施: Topotecan (Drug)
结局指标
主要结局
Number of Adverse Events
时间窗: Through study completion- an average of 2 years
The AE Profile will be determined by the number of AEs regardless of severity
Number of Serious Adverse Events
时间窗: Through study completion- an average of 2 years
The SAE Profile will be determined by the number of SAEs
次要结局
- Maximum Plasma Concentration (Cmax)(Cycle 1 Day 1, at 0, .5, 1, 2, 4, 6 and 24 hours post-dose and Day 15 at 0 and end of infusion)
- Time to Maximum Plasma Concentration for ME-344 (Tmax)(Cycle 1 Day 1, at 0, .5, 1, 2, 4, 6 and 24 hours post-dose and Day 15 at 0 and end of infusion)
- Minimum Plasma Concentration (Cmin) of ME-344(Cycle 1 Day 1, at 0, .5, 1, 2, 4, 6 and 24 hours post-dose and Day 15 at 0 and end of infusion)
- Mean Terminal Half-life (t 1/2)(Cycle 1 Day 1, at 0, .5, 1, 2, 4, 6 and 24 hours post-dose and Day 15 at 0 and end of infusion)
- Estimate Overall Response Rate for ME-344 Given in Combination With Topotecan(Response was assessed throughout the trial up to 13 months)
- Estimate the Overall Survival (OS)(Up to 2 years)
研究者
研究点 (10)
Loading locations...
相似试验
撤回
1 期
Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung CancerLung Cancer, Non-Small CellNCT01938456GlaxoSmithKline
已完成
3 期
A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1Hepatitis C Virus Genotype-1NCT01479868Janssen R&D Ireland109
已完成
1 期
A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung CancerLung CancerNon-small Cell Lung CancerNSCLCNCT02000947MedImmune LLC459
终止
2 期
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)Non-hodgkin LymphomaNCT03645395Molecular Templates, Inc.9
已完成
2 期
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and SimeprevirChronic Hepatitis CNCT02569710Alios Biopharma Inc.161